1,5-Anhydroglucitol

The role of 1,5-AG was first inferred by Akanuma in 1981 {{cite journal |vauthors=Akanuma Y, Ogawa K, Yamanouchi T, Mashiko S, Oka Y, Kosaka K, Akanuma H |title=Decreased plasma 1,5-anhydroglucitol in diabetic patients |journal=Diabetes |volume=30 |issue=Suppl. 1 |pages=124A |year=1981}} when he demonstrated decreased 1,5-AG levels in diabetic patients. This observation was enhanced in 1983 when it was seen that plasma 1,5-AG fell to undetectable levels in diabetic patients who did not receive insulin.{{cite journal |vauthors=Yoshioka S, Saitoh S, Negishi C, Fujisawa T, Takatani O, Imura M, Funagashi M |title=Variations of 1-deoxyglucose (1,5-anhydroglucitol) content in plasma from patients with insulin-dependent diabetes mellitus. |journal=Clin. Chem. |volume=29 |issue=7 |pages=1396–8 |year=1983 |doi=10.1093/clinchem/29.7.1396 |pmid=6345028 }} Further studies{{cite journal |vauthors=Yamanouchi T, etal |title=Clinical usefulness of serum 1,5-anhydroglucitol in monitoring glycemic control. |journal=The Lancet |volume=347 |issue=9014 |pages=1514–8 |year=1996 |pmid=8684103 |doi=10.1016/S0140-6736(96)90672-8|s2cid=22244005 }} showed that patients receiving medication to lower blood glucose had lasting improvement in 1,5-AG levels. If medication stopped, 1,5-AG decreased to pre-treatment levels. In 2003, 1,5-AG began to be looked at by researchers in the United States and was shown to be a valuable short-term glycemic monitor.{{cite journal |vauthors=Buse JB, Freeman JL, Edelman SV, Jovanovic L, McGill JB |title=Serum 1,5-anhydroglucitol(GlycoMark{{sup|TM}}): a short-term glycemic marker. |journal=Diabetes Technol Ther. |volume=5 |issue=3 |pages=355–63 |year=2003 |pmid=12828817 |doi=10.1089/152091503765691839}}{{cite journal |vauthors=McGill JB, Cole TG, Nowatzke W, Houghton S, Ammirati EB, Gautille T, Sarno MJ |title=Circulating 1,5-anhydroglucitol levels in adult patients with diabetes reflect longitudinal changes of glycemia: a U.S. trial of the GlycoMark{{sup|TM}} assay. |journal=Diabetes Care |volume=27 |issue=8 |pages=1859–65 |year=2004 |pmid= 15277408|doi=10.2337/diacare.27.8.1859|doi-access=free }} In 2006, 1,5-AG showed its most compelling clinical use when it was demonstrated that an assay (GlycoMark, developed by Nippon Kayaku, Inc.) for postprandial hyperglycemia was able to differentiate two patients who had similar, near goal, hemoglobin A1c values, yet very different glucose profiles as shown by continuous blood glucose monitoring - one of the patients having excessive glycemic variability.{{cite journal |vauthors=Dungan KM, Buse JB, Largay J, Kelly MM, Button EA, Wittlin S |title=1,5-anhydroglucitol and postprandial hyperglycemia as measured by continuous glucose monitoring system in moderately controlled patients with diabetes. |journal=Diabetes Care |volume=29 |issue=6 |pages=1214–9 |year=2006 |pmid=16731998 |doi=10.2337/dc06-1910|doi-access=free }} In 2014, 1,5-AG in saliva was shown to mirror 1,5-AG in blood, indicating that it could be used as a noninvasive marker of short-term glycemic control.{{cite journal |vauthors=Mook-Kanamori DO, Selim MM, Takiddin AH, Al-Homsi H, Al-Mahmoud KA, Al-Obaidli A, Zirie MA, Rowe J, Yousri NA, Karoly ED, Kocher T, Sekkal Gherbi W, Chidiac OM, Mook-Kanamori MJ, Abdul Kader S, Al Muftah WA, McKeon C, Suhre K |title=1,5-Anhydroglucitol in saliva is a noninvasive marker of short-term glycemic control. |journal=J Clin Endocrinol Metab |volume=99 |issue=3 |pages=479–83 |year=2013 |pmid=24423354 |doi=10.1210/jc.2013-3596|doi-access=free }}

1,5-AG is ingested from nearly all foods during the course of a regular diet and is nearly 100% non-metabolized. It is carried in the blood stream and filtered by the glomerulus, where it enters the kidney.{{Cite journal |last1=Kucharska |first1=Alicja |last2=Szmurło |first2=Agnieszka |last3=Sińska |first3=Beata |date=May 4, 2016 |title=Significance of diet in treated and untreated acne vulgaris |journal=Advances in Dermatology and Allergology/Postȩpy Dermatologii i Alergologii |volume=33 |issue=2 |pages=81–86 |doi=10.5114/ada.2016.59146 |issn=1642-395X |pmc=4884775 |pmid=27279815}} Once in the kidney, 1,5-AG is re-absorbed back into the blood through the renal proximal tubule. A small amount, equal to the amount ingested, of 1,5-AG is released in the urine to maintain a constant amount in the blood and tissue.{{Cite journal |last1=Copur |first1=Sidar |last2=Onal |first2=Emine M. |last3=Afsar |first3=Baris |last4=Ortiz |first4=Alberto |last5=van Raalte |first5=Daniel H. |last6=Cherney |first6=David Z. |last7=Rossing |first7=Peter |last8=Kanbay |first8=Mehmet |date=2020-11-01 |title=Diabetes mellitus in chronic kidney disease: Biomarkers beyond HbA1c to estimate glycemic control and diabetes-dependent morbidity and mortality |url=https://www.sciencedirect.com/science/article/pii/S105687272030475X |journal=Journal of Diabetes and Its Complications |language=en |volume=34 |issue=11 |pages=107707 |doi=10.1016/j.jdiacomp.2020.107707 |pmid=32861562 |s2cid=221385292 |issn=1056-8727|url-access=subscription }}

Glucose is a competitive inhibitor of the re-absorption. If blood glucose values rise over 180 mg/dL for any period of time, the kidney cannot re-absorb all glucose back into the blood, leading to increased excretion in the urine (glucosuria).{{Cite journal |last=Bailey |first=Clifford J. |date=January 5, 2011 |title=Renal glucose reabsorption inhibitors to treat diabetes |url=https://pubmed.ncbi.nlm.nih.gov/21211857/ |journal=Trends in Pharmacological Sciences |volume=32 |issue=2 |pages=63–71 |doi=10.1016/j.tips.2010.11.011 |issn=1873-3735 |pmid=21211857}} As a result, blood levels of 1,5-AG decrease immediately, and continue to decrease until glucose values go below 180 mg/dL.{{Cite web |last=Qure Healthcare, LLC |date=2020-10-06 |others=GlycoMark, Inc |title=Glucose Control Using 1,5-AG: Randomized Controlled Trial |url=https://clinicaltrials.gov/ct2/show/NCT03765164}} Once the hyperglycemia is corrected, 1,5-AG begins to be re-absorbed from the kidney back into the blood at a steady rate.{{Cite journal |last1=Yamanouchi |first1=T. |last2=Akanuma |first2=Y. |date=October 1, 1994 |title=Serum 1,5-anhydroglucitol (1,5 AG): new clinical marker for glycemic control |url=https://pubmed.ncbi.nlm.nih.gov/7859616/ |journal=Diabetes Research and Clinical Practice |volume=24 Suppl |pages=S261–268 |doi=10.1016/0168-8227(94)90259-3 |issn=0168-8227 |pmid=7859616}}{{Cite journal |last1=Won |first1=Jong Chul |last2=Park |first2=Cheol-Young |last3=Park |first3=Hyo-Soon |last4=Kim |first4=Ji Hoom |last5=Choi |first5=Eun Sook |last6=Rhee |first6=Eun Jung |last7=Lee |first7=Won Young |last8=Oh |first8=Ki Won |last9=Kim |first9=Sun Woo |last10=Park |first10=Sung Woo |date=February 3, 2009 |title=1,5-Anhydroglucitol reflects postprandial hyperglycemia and a decreased insulinogenic index, even in subjects with prediabetes and well-controlled type 2 diabetes |url=https://pubmed.ncbi.nlm.nih.gov/19187997/ |journal=Diabetes Research and Clinical Practice |volume=84 |issue=1 |pages=51–57 |doi=10.1016/j.diabres.2009.01.002 |issn=1872-8227 |pmid=19187997}} If a person's glucose levels remain below 180 mg/dL for approximately 4 weeks, 1,5-AG will return to its normal levels. As a result, measurement of the level of 1,5-AG in the blood is a test for a recent history of hyperglycemic episodes.{{Cite web |last=CDC |date=2021-04-28 |title=Manage Blood Sugar |url=https://www.cdc.gov/diabetes/managing/manage-blood-sugar.html |access-date=2022-11-25 |website=Centers for Disease Control and Prevention |language=en-us}}

The GlycoMark test is cleared by the FDA to be sold and marketed for the intermediate term monitoring of glycemic control in people with diabetes. It is available through most major reference laboratories, including Quest Diagnostics and Labcorp or may be performed in a hospital or physician's office. A comprehensive evaluation of the assay has been described in the literature.{{cite journal |vauthors=Nowatzke W, Sarno MJ, Birch NC, Stickle DF, Eden T, Cole TG |title=Evaluation of an assay for serum 1,5-anhydroglucitol (GlycoMark{{sup|TM}}) and determination of reference intervals on the Hitachi 917 analyzer. |journal=Clin Chim Acta |volume=350 |issue=1–2 |pages=201–9 |year=2004 |pmid=15530479 |doi=10.1016/j.cccn.2004.08.013}}

The assay can be run on almost any open chemistry analyzer, including those found in physician office laboratories. Two reactions take place during the measurement:

Reaction 1 is a pretreatment of the sample performed by adding glucokinase to convert glucose to glucose 6-phosphate in the presence of adenosine triphosphate, pyruvate kinase, and phosphoenol pyruvate. The purpose of this step is to alter glucose, which is found in the blood sample, so that it can not react during reaction 2.

Reaction 2 uses pyranose oxidase to oxidize the second hydroxyl of 1,5-AG, generating hydrogen peroxide. The amount of hydrogen peroxide is detected by colorimetry using peroxidase, and is in direct relationship to the serum 1,5-AG concentration.

{{unreferenced section|date=August 2018}}

Results are in μg/mL. Lower values indicate worsening glucose control, with more frequent and prolonged glucose values over 180 mg/dL. 10 μg/mL of 1,5-AG correlates to an average post meal glucose of 185 mg/dL, and is the target value in people with diabetes. Values over 10 μg/mL indicate glucose on average is below 180 mg/dL. Those with values below 10 μg/mL could benefit from nutritional counseling, and medications which target post meal glucose spikes, such as pramlintide, exenatide, sitagliptin, saxagliptin, repaglinide or rapid acting insulins.

• Glycated hemoglobin
• Diabetes

{{reflist|2}}

• {{Commonscatinline}}

{{Diabetes}}

{{DEFAULTSORT:Anhydroglucitol, 1, 5-}}

Category:Deoxy sugars

Category:Diabetes-related tests